Last reviewed · How we verify
Higher Dose UFH
At a glance
| Generic name | Higher Dose UFH |
|---|---|
| Sponsor | Population Health Research Institute |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Laboratory confirmed SARS-CoV-2 infection
Key clinical trials
- Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy (PHASE2)
- Higher vs. Lower Dose Heparin for PCI (NA)
- Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies (PHASE2, PHASE3)
- Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care (PHASE3)
- Low Dose Thrombolysis, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism (PHASE3)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Evaluation of the Standard Catheter-directed Thrombolysis Effectiveness in Intermediate-High-Risk Pulmonary Embolism Patients (NA)
- Standard vs High Dose of Unfractionated Heparin in the Incidence of Radial Artery Occlusion (DEFINITION) Trial. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Higher Dose UFH CI brief — competitive landscape report
- Higher Dose UFH updates RSS · CI watch RSS
- Population Health Research Institute portfolio CI